Activation of PPARδ alters lipid metabolism in db/db mice

被引:277
|
作者
Leibowitz, MD
Fiévet, C
Hennuyer, N
Peinado-Onsurbe, J
Duez, H
Berger, J
Cullinan, CA
Sparrow, CP
Baffic, J
Berger, GD
Santini, C
Marquis, RW
Tolman, RL
Smith, RG
Moller, DE
Auwerx, J
机构
[1] Merck Res Labs, Dept Lipid Biochem, Rahway, NJ 07065 USA
[2] Merck Res Labs, Dept Med Chem, Rahway, NJ 07065 USA
[3] Inst Pasteur Lille, INSERM, U325, F-59019 Lille, France
[4] Merck Res Labs, Dept Mol Endocrinol, Rahway, NJ 07065 USA
关键词
peroxisome proliferator-activated receptor delta agonist; peroxisome proliferator-activated receptor; lipid metabolism;
D O I
10.1016/S0014-5793(00)01554-4
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Peroxisome proliferator-activated receptors (PPARs) are nuclear receptors, which heterodimerize with the retinoid X receptor and bind to peroxisome proliferator response elements in the promoters of regulated genes. Despite the wealth of information available on the function of PPAR alpha and PPAR gamma, relatively little is known about the most widely expressed PPAR subtype, PPAR delta. Here we show that treatment of insulin resistant db/db mice with the PPAR delta agonist L-165041, at doses that had no effect on either glucose or triglycerides, raised total plasma cholesterol concentrations. The increased cholesterol was primarily associated,vith high density lipoprotein (HDL) particles, as shown by fast protein liquid chromatography analysis. These data,were corroborated by the chemical analysis of the lipoproteins isolated by ultracentrifugation, demonstrating that treatment with L-165041 produced an increase in circulating HDL without major changes in very low or low density lipoproteins. White adipose tissue lipoprotein lipase activity,vas reduced following treatment with the PPAR delta ligand, but was increased by a PPAR gamma agonist. These data suggest both that PPAR delta is involved in the regulation of cholesterol metabolism in db/db mice and that PPAR delta ligands could potentially have therapeutic value. (C) 2000 Federation of European Biochemical Societies.
引用
收藏
页码:333 / 336
页数:4
相关论文
共 50 条
  • [31] Improved cerebral energetics and ketone body metabolism in db/db mice
    Andersen, Jens V.
    Christensen, Sofie K.
    Nissen, Jakob D.
    Waagepetersen, Helle S.
    JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 2017, 37 (03): : 1137 - 1147
  • [32] INVIVO COLLAGEN-METABOLISM IN SPONTANEOUSLY DIABETIC (DB/DB) MICE
    BOWERSOX, JC
    EXPERIMENTAL AND MOLECULAR PATHOLOGY, 1986, 45 (02) : 221 - 226
  • [33] Improved cerebral energetics and ketone body metabolism in db/db mice
    Andersen, J. V.
    Nissen, J.
    Christensen, S. K.
    Waagepetersen, H.
    JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 2017, 37 : 487 - 488
  • [34] Artemether Regulates Metaflammation to Improve Glycolipid Metabolism in db/db Mice
    Fu, Wei
    Ma, Yujin
    Li, Liping
    Liu, Jie
    Fu, Liujun
    Guo, Yu
    Zhang, Zhiyin
    Li, Jiaxi
    Jiang, Hongwei
    DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2020, 13 : 1703 - 1713
  • [35] The total flavonoids from Selaginella tamariscina (beauv.) Spring improve glucose and lipid metabolism in db/db mice
    Wang, Xiaolan
    Feng, Aozi
    Yuan, Peipei
    Fu, Yang
    Bai, Zhiyao
    Zhou, Ning
    Zheng, Xiaoke
    IRANIAN JOURNAL OF BASIC MEDICAL SCIENCES, 2020, 23 (10) : 1286 - 1292
  • [36] Transcriptomics Reveals the Mechanism of Rosa roxburghii Tratt Ellagitannin in Improving Hepatic Lipid Metabolism Disorder in db/db Mice
    Tan, Yunyun
    Tan, Shuming
    Ren, Tingyuan
    Yu, Lu
    Li, Pei
    Xie, Guofang
    Chen, Chao
    Yuan, Meng
    Xu, Qing
    Chen, Zhen
    NUTRIENTS, 2023, 15 (19)
  • [37] Effects of small interfering RNA-mediated hepatic glucagon receptor inhibition on lipid metabolism in db/db mice
    Han, Seongah
    Akiyama, Taro E.
    Previs, Stephen F.
    Herath, Kithsiri
    Roddy, Thomas P.
    Jensen, Kristian K.
    Guan, Hong-Ping
    Murphy, Beth A.
    McNamara, Lesley A.
    Shen, Xun
    Strapps, Walter
    Hubbard, Brian K.
    Pinto, Shirly
    Li, Cai
    Li, Jing
    JOURNAL OF LIPID RESEARCH, 2013, 54 (10) : 2615 - 2622
  • [38] Effects of the novel oral antidiabetic agent HQL-975 on glucose and lipid metabolism in diabetic db/db mice
    Ishikawa, Y
    Watanabe, K
    Takeno, H
    Tani, T
    ARZNEIMITTEL-FORSCHUNG-DRUG RESEARCH, 1998, 48 (03): : 245 - 250
  • [39] Increase in weight induced by muraglitazar, a dual PPARα/γ agonist, in db/db mice:: adipogenesis/or oedema?
    Mittra, S.
    Sangle, G.
    Tandon, R.
    Sharma, S.
    Roy, S.
    Khanna, V.
    Gupta, A.
    Sattigeri, J.
    Sharma, L.
    Priyadarsiny, P.
    Khattar, S. K.
    Bora, R. S.
    Saini, K. S.
    Bansal, V. S.
    BRITISH JOURNAL OF PHARMACOLOGY, 2007, 150 (04) : 480 - 487
  • [40] TEAVIGOTM improves efficacy of the PPARγ agonist rosiglitazone but inhibits associated adiposity in db/db mice
    Wolfram, S
    Raederstorff, D
    Elste, V
    Weber, P
    FASEB JOURNAL, 2004, 18 (04): : A135 - A135